2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 64

Rab4A Controls mTOR Pathway Activation, Pro-inflammatory Lineage Development, and Disease Pathogenesis in Lupus-prone Mice

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 82

Rab4A Increases Mitochondrial Oxidative Stress and Glutathione Disulfide Accumulation That Underlie Neurobehavioral Changes in Lupus-Prone Mice

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 584

Radiographic Association of Hip and SI Joints in Ankylosing Spondylitis Patients

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 350

Rapid Reduction in Uric Acid Is Associated with Recurrent Cardiovascular Events

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 244

Real-World Evidence Associated with the Treatment of Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 419

Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 204

Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 203

Recent Use, Missed Doses and Discontinuation of Infliximab in a Population-Based Cohort: Comparisons of Biosimilar and Originator Exposures

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 631

Recognition of Inflammatory Back Pain by US Healthcare Providers and Barriers to Specialist Referral

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 736

Reduced Circulating Levels of Inorganic Pyrophosphate Are Associated with Ectopic Calcification in Scleroderma Spectrum Disorders

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 31

Regulation of Neutrophil Extracellular Traps by Apremilast (phosphodiesterase 4 Inhibition)

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 619

Relation of Therapies for Ankylosing Spondylitis to Risk of Total Hip and Knee Arthroplasty

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 213

Relationship Between a History of Abuse and Fibromyalgia Symptoms and Severity: Data from the Cleveland Clinic Fibromyalgia Registry

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 710

Relationship Between High-Resolution Computer Tomography and FVC% Predicted for Classification of Pulmonary Hypertension in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 138

Relationship Between Recurrent Thrombosis and the Antiphospholipid Antibodies Profile in a Cohort of Patients with Antiphospholipid Syndrome

Antiphospholipid Syndrome Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].